348 related articles for article (PubMed ID: 33213825)
1. COVID-19 and cardiovascular disease.
Guijarro C
Clin Investig Arterioscler; 2020; 32(6):263-266. PubMed ID: 33213825
[No Abstract] [Full Text] [Related]
2. Statins in COVID-19: is there any foundation?
Lima Martínez MM; Contreras MA; Marín W; D'Marco L
Clin Investig Arterioscler; 2020; 32(6):278-281. PubMed ID: 32718669
[TBL] [Abstract][Full Text] [Related]
3. Angiotensin-converting-enzyme inhibitors (ACE inhibitors) and angiotensin II receptor blocker (ARB) use in COVID-19 prevention or treatment: A paradox.
Javanmard SH; Heshmat-Ghahdarijani K; Vaseghi G
Infect Control Hosp Epidemiol; 2021 Jan; 42(1):118-119. PubMed ID: 32362297
[No Abstract] [Full Text] [Related]
4. Commentary: Statins, COVID-19, and coronary artery disease: killing two birds with one stone.
Ganjali S; Bianconi V; Penson PE; Pirro M; Banach M; Watts GF; Sahebkar A
Metabolism; 2020 Dec; 113():154375. PubMed ID: 32976855
[No Abstract] [Full Text] [Related]
5. COVID-19 and Cardiovascular Disease: From Bench to Bedside.
Chung MK; Zidar DA; Bristow MR; Cameron SJ; Chan T; Harding CV; Kwon DH; Singh T; Tilton JC; Tsai EJ; Tucker NR; Barnard J; Loscalzo J
Circ Res; 2021 Apr; 128(8):1214-1236. PubMed ID: 33856918
[TBL] [Abstract][Full Text] [Related]
6. Cathepsin L in COVID-19: From Pharmacological Evidences to Genetics.
Gomes CP; Fernandes DE; Casimiro F; da Mata GF; Passos MT; Varela P; Mastroianni-Kirsztajn G; Pesquero JB
Front Cell Infect Microbiol; 2020; 10():589505. PubMed ID: 33364201
[TBL] [Abstract][Full Text] [Related]
7. Statins and PCSK9 inhibitors: What is their role in coronavirus disease 2019?
Barkas F; Milionis H; Anastasiou G; Liberopoulos E
Med Hypotheses; 2021 Jan; 146():110452. PubMed ID: 33333472
[TBL] [Abstract][Full Text] [Related]
8. The Ineluctable Role of ACE-2 Receptors in SARS COV-2 Infection and Drug Repurposing as a Plausible SARS COV-2 Therapy: A Concise Treatise.
Joseph S; Nair B; Nath LR
Curr Mol Med; 2021; 21(10):888-913. PubMed ID: 33563197
[TBL] [Abstract][Full Text] [Related]
9. SARS-CoV-2, ACE2 expression, and systemic organ invasion.
Ashraf UM; Abokor AA; Edwards JM; Waigi EW; Royfman RS; Hasan SA; Smedlund KB; Hardy AMG; Chakravarti R; Koch LG
Physiol Genomics; 2021 Feb; 53(2):51-60. PubMed ID: 33275540
[TBL] [Abstract][Full Text] [Related]
10. Potential therapeutic approaches for the early entry of SARS-CoV-2 by interrupting the interaction between the spike protein on SARS-CoV-2 and angiotensin-converting enzyme 2 (ACE2).
Xiang Y; Wang M; Chen H; Chen L
Biochem Pharmacol; 2021 Oct; 192():114724. PubMed ID: 34371003
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of ACE2-Spike Interaction by an ACE2 Binder Suppresses SARS-CoV-2 Entry.
Shin YH; Jeong K; Lee J; Lee HJ; Yim J; Kim J; Kim S; Park SB
Angew Chem Int Ed Engl; 2022 Mar; 61(11):e202115695. PubMed ID: 35043545
[TBL] [Abstract][Full Text] [Related]
12. Receptor utilization of angiotensin-converting enzyme 2 (ACE2) indicates a narrower host range of SARS-CoV-2 than that of SARS-CoV.
Wang Q; Qiu Y; Li JY; Liao CH; Zhou ZJ; Ge XY
Transbound Emerg Dis; 2021 May; 68(3):1046-1053. PubMed ID: 32794346
[TBL] [Abstract][Full Text] [Related]
13. Impact of renin-angiotensin system inhibitors use on mortality in severe COVID-19 patients with hypertension: a retrospective observational study.
Zhong Y; Zhao L; Wu G; Hu C; Wu C; Xu M; Dong H; Zhang Q; Wang G; Yu B; Lv J; Wu C; Zhang S; Cao C; Shu L; Pan Y; Liu X; Wu F
J Int Med Res; 2020 Dec; 48(12):300060520979151. PubMed ID: 33322988
[TBL] [Abstract][Full Text] [Related]
14. COVID-19 and cardiovascular consequences: Is the endothelial dysfunction the hardest challenge?
Del Turco S; Vianello A; Ragusa R; Caselli C; Basta G
Thromb Res; 2020 Dec; 196():143-151. PubMed ID: 32871306
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of S-protein RBD and hACE2 Interaction for Control of SARSCoV- 2 Infection (COVID-19).
Nayak SK
Mini Rev Med Chem; 2021; 21(6):689-703. PubMed ID: 33208074
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular disease in patients with COVID-19: evidence from cardiovascular pathology to treatment.
Luo J; Zhu X; Jian J; Chen X; Yin K
Acta Biochim Biophys Sin (Shanghai); 2021 Mar; 53(3):273-282. PubMed ID: 33428706
[TBL] [Abstract][Full Text] [Related]
17. Angiotensin-converting enzyme as a new immunologic target for the new SARS-CoV-2.
Hallaj S; Ghorbani A; Mousavi-Aghdas SA; Mirza-Aghazadeh-Attari M; Sevbitov A; Hashemi V; Hallaj T; Jadidi-Niaragh F
Immunol Cell Biol; 2021 Feb; 99(2):192-205. PubMed ID: 32864784
[TBL] [Abstract][Full Text] [Related]
18. Viral Coagulopathy in Patients With COVID-19: Treatment and Care.
Kipshidze N; Dangas G; White CJ; Kipshidze N; Siddiqui F; Lattimer CR; Carter CA; Fareed J
Clin Appl Thromb Hemost; 2020; 26():1076029620936776. PubMed ID: 32687449
[TBL] [Abstract][Full Text] [Related]
19. Variable Clinical Manifestations of COVID-19: Viral and Human Genomes Talk.
Imani-Saber Z; Vaseghi H; Mahdian M; Safari F; Ghadami M
Iran J Allergy Asthma Immunol; 2020 Oct; 19(5):456-470. PubMed ID: 33463113
[TBL] [Abstract][Full Text] [Related]
20. Telmisartan as tentative angiotensin receptor blocker therapeutic for COVID-19.
Rothlin RP; Vetulli HM; Duarte M; Pelorosso FG
Drug Dev Res; 2020 Nov; 81(7):768-770. PubMed ID: 32356926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
